Through database mining, microarray analysis, proteomics, transcriptomics, and other approaches, several studies [19–23] have unveiled the elevated expression of CALU in lung cancer, colon cancer, glioma, and breast cancer, positioning it as a promising biomarker. The gene discussed is CALU; the disease is breast carcinoma.